PF-Atlas › Clinical Trials › NCT06192004

Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD

None · Not specified

Registry ID

NCT06192004

Phase

Not specified

Status

Terminated

Drug / intervention

None (Observational Study)

Sponsor

AstraZeneca

Start

2024-01-05

Enrollment

Locations

About this trial

This is an observational, prospective, multicenter study conducted in the US to gather evidence in the context of lung cancer to complement the development of a digital solution. Patients initiating treatment for non-small cell lung cancer (NSCLC) will be prospectively followed to characterize risk factors, signs, and symptoms leading to onset, diagnosis, and treatment of pneumonitis/ILD should it occur.

View NCT06192004 on ClinicalTrials.gov →

Explore related

All None trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT06192004 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.